杭州安道药业有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exposition and Announces FDA Authorization of Investigational New Drug (IND) Application for AND017 for Clinical Trial in Sickle Cell Disease (SCD) 2024-12-12 16:25
KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I 2024-10-29 05:42
KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD) 2024-10-26 00:33
KIND Announces Late-Breaking Abstract Accepted for Presentation on AND017 Clinical Trials to Treat Anemia in Chronic Kidney Disease (CKD) at ASN - Kidney Week 2024 2024-10-17 15:44
Kind Pharmaceuticals Announces Settlement 2024-04-17 00:17
1